Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence. Many of the current biologic disease-modifying antirheumatic drugs on the market are injectables, leaving a void to be filled for a product that can be taken orally. The most advanced of these approaches, the Janus kinase (JAK) inhibitors, are oral drugs that have not only made a breakthrough in RA, but also other skin conditions. (The full article  is published in the November issue of Hospital Pharmacy)

​Track investigational drugs and find out their current status in the Prescribe Right Pharmaceutical Pipeline Tracker